PHARMACOM RETAROS – Retatrutide -15 MG / VIAL -2 ML VIAL

RETAROS

 – Retatrutide – 15 MG / VIAL – 2 ML VIAL – Pharmacom LABS

• RETAROS 15 MG is a retatrutide-based product designed for advanced weight management and metabolic improvement.
• Retatrutide is a triple incretin receptor agonist (GLP-1, GIP, and Glucagon), providing a comprehensive approach to appetite control, energy expenditure, and glucose regulation.
• The compound reduces appetite, increases satiety, and significantly lowers caloric intake while enhancing fat oxidation and overall metabolic rate.
• Retatrutide improves insulin sensitivity and glycemic control, contributing to better blood glucose regulation.
• Clinical observations show positive effects on lipid profiles, reductions in systolic blood pressure, and a lowered cardiovascular risk associated with excess body weight.
• The majority of weight loss observed during retatrutide administration is primarily due to adipose tissue reduction.
• The long active half-life allows for once-weekly subcutaneous injection.
• RETAROS does not interfere with sex hormone production, making it suitable for use by both men and women, and no post-cycle therapy (PCT) is required after discontinuation.
• RETAROS is supplied as a peptide dry powder and must be reconstituted with water for injection before use.

Retatrutide